Iwamoto Hiroaki, Izumi Kouji, Natsagdorj Ariunbold, Makino Tomoyuki, Nohara Takahiro, Shigehara Kazuyoshi, Kadono Yoshifumi, Mizokami Atsushi
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
In Vivo. 2018 Jul-Aug;32(4):899-903. doi: 10.21873/invivo.11326.
The effectiveness and safety of pegfilgrastim during bleomycin, etoposide and cisplatin (BEP) chemotherapy have not yet been investigated.
Patients with germ cell tumors (GCTs) who received pegfilgrastim during BEP at the Kanazawa University Hospital between January 2014 and December 2016 were retrospectively analyzed. The frequency of adverse events and effectiveness in inhibiting neutropenia were compared between cycles using pegfilgrastim and those using filgrastim.
Pegfilgrastim and filgrastim were administered in 13 and 22 cycles, respectively. The absolute neutrophil count at the nadir was significantly lower in patients receiving pegfilgrastim than in those receiving filgrastim (p=0.003). The duration of grade 2-4 neutropenia in cycles using filgrastim was significantly longer than that in those pegfilgrastim (p=0.01). No significant differences in the incidence of febrile neutropenia and serious adverse events were observed.
Pegfilgrastim can be safely and effectively administrated during BEP for patients with GCT.
培非格司亭在博来霉素、依托泊苷和顺铂(BEP)化疗期间的有效性和安全性尚未得到研究。
对2014年1月至2016年12月期间在金泽大学医院接受BEP化疗并使用培非格司亭的生殖细胞肿瘤(GCT)患者进行回顾性分析。比较使用培非格司亭的周期和使用非格司亭的周期之间不良事件的发生频率以及抑制中性粒细胞减少的有效性。
分别有13个周期和22个周期使用了培非格司亭和非格司亭。接受培非格司亭治疗的患者最低点的绝对中性粒细胞计数显著低于接受非格司亭治疗的患者(p = 0.003)。使用非格司亭的周期中2-4级中性粒细胞减少的持续时间显著长于使用培非格司亭的周期(p = 0.01)。发热性中性粒细胞减少症的发生率和严重不良事件未观察到显著差异。
对于GCT患者,在BEP化疗期间可以安全有效地使用培非格司亭。